RESEARCH TRIANGLE PARK – Thursday was not a good day for North Carolina life science companies. While BioDelivery Sciences reported a big profit, BioCryst, Aerie, TransEnterix, Chimerix and vTv Therapeutics all reported signifcant losses.
Here’s a recap:
- BioDelivery’s profit
RALEIGH – BioDelivery Sciences International Inc. (BDSI) on Thursday reported third-quarter earnings of $9.4 million.
The Raleigh-based company said it had profit of 9 cents per share.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 6 cents per share.
The specialty pharmaceutical company posted revenue of $39.4 million in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $38.9 million.
The company’s shares closed at $3.46. A year ago, they were trading at $5.94.
- BioCryst loses $46.1M
DURHAM – BioCryst Pharmaceuticals Inc. (BCRX) on Thursday reported a loss of $46.1 million in its third quarter.
The Durham-based company said it had a loss of 26 cents per share.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 25 cents per share.
The drugmaker posted revenue of $6.1 million in the period, which topped Street forecasts. Four analysts surveyed by Zacks expected $4.3 million.
The company’s shares closed at $4.27. A year ago, they were trading at $2.16.
- Aerie reports $39.6M loss
DURHAM – Aerie Pharmaceuticals Inc. (AERI) on Thursday reported a loss of $39.6 million in its third quarter.
On a per-share basis, the North Carolina, North Carolina-based company said it had a loss of 86 cents. Losses, adjusted for non-recurring costs, were 65 cents per share.
The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 81 cents per share.
The drugmaker posted revenue of $20.1 million in the period, also exceeding Street forecasts. Six analysts surveyed by Zacks expected $19.2 million.
Aerie shares have declined 56% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $10.73, a drop of 55% in the last 12 months.
- TransEnterix loses $15.1M
MORRISVILLE – TransEnterix Inc. (TRXC) on Thursday reported a loss of $15.1 million in its third quarter.
On a per-share basis, the Morrisville-based company said it had a loss of 15 cents. Losses, adjusted for amortization costs and non-recurring costs, were 12 cents per share.
The maker of surgical robots and medical instruments posted revenue of $814,000 in the period.
In the final minutes of trading on Thursday, the company’s shares hit 40 cents. A year ago, they were trading at $3.63.
- Chimerix takes $11.4M hit
DURHAM – Chimerix Inc. (CMRX) on Thursday reported a loss of $11.4 million in its third quarter.
On a per-share basis, the Durham-based company said it had a loss of 18 cents.
The biopharmaceutical company posted revenue of $1.6 million in the period.
The company’s shares closed at $3.06. A year ago, they were trading at $1.46.
- vTv Therapeutics reports $1.5M loss
HIGH POINT – VTv Therapeutics Inc. (VTVT) on Thursday reported a loss of $1.5 million in its third quarter.
The High Point, North Carolina-based company said it had a loss of 3 cents per share.
The biopharmaceutical company posted revenue of $7,000 in the period.
In the final minutes of trading on Thursday, the company’s shares hit $1.70. A year ago, they were trading at $1.39.
